institutCurie

A leading player in the fight against cancer, Institut Curie brings together an internationally-renowned research centre and an advanced hospital group that provides care for all types of cancer – including the rarest forms.
Founded in 1909 by Nobel laureate Marie Curie, Institut Curie comprises three sites (Paris, Saint-Cloud and Orsay), where more than 3,400 members of staff are dedicated to achieving three objectives: hospital care; scientific research; and the sharing of knowledge and the preserving of legacy.

INSTITUT CARNOT Curie Cancer

Since 2011, Institut Curie is certified "Institut Carnot Curie Cancer". The Carnot label is a label of excellence granted to academic research structures with proven high quality and involvement in partnership research. Curie Cancer offers industrial partners the opportunity to set up research collaborations, benefiting from the expertise of the Institut Curie teams, for the development of innovative therapeutic solutions against cancers from the therapeutic target to clinical validation.

CONTACT INFO:
contact.techtransfer@curie.fr
26 rue d'Ulm, 75005 Paris France

techtransfer.institut-curie.org

Carnot Curie cancer
@CurieCancer

Graphics DOMINIQUE HAMOT / LAURENT LOISON. Photography NOAK/LE BAR FLORÉAL, ARNAUD ECHARD/CNRS, YOULIA KIROVA, CÉCILE LEDUC, ERIC BOUVET, NICOLAS KRIEF, FLORENCE LEVILLAIN/SIGNATURES. NICOLAS KRIEF, PEDRO LOMBARDI, CHRISTOPHE HARGOUES, DÉPARTEMENT DE RADIOTHÉRAPIE, URIEL CHANTRAINE/INSTITUT CURIE. NOUN PROJECT. **ONCOPED 2019-V1**

PEDIATRIC ONCOLOGY

institutCurie

INSTITUT CARNOT Curie Cancer

techtransfer.institut-curie.org



ACCELERATE **TECHNOLOGICAL INNOVATION** AND MARKET ACCESS THROUGH **PARTNERSHIPS**

Institut Curie Technology Transfer and Industrial Partnership Office is the quickest gateway to the state-of-the-art innovations happening at Institut Curie.

Our key mission is to connect innovators with the business & investor communities and to offer a single access point for creating R&D partnerships with Curie experts and technology licensing.

Our ambition is to ensure that your project receive the greatest chance of actually reaching patients.

Pediatric and adolescent & young adults Oncology is often described as a model for interdisciplinary care in cancer. Integration of biological and translational research with clinical management of patients is now becoming an important part of interdisciplinary health care. Institut Curie certainly has the foundations to stand at the forefront of this new practice of medicine.

Let's work together and take advantage of our recognized expertise labelled Carnot Curie Cancer!

AMAURY MARTIN, PHD
DIRECTOR, TECHNOLOGY TRANSFER & INDUSTRIAL PARTNERSHIPS OFFICE, INSTITUT CURIE
DIRECTOR, INSTITUT CARNOT CURIE CANCER



KEY FIGURES
TECH TRANSFER OFFICE
2018 DATA

70 NEW R&D AGREEMENTS
6 M€ INCOME IN R&D CONTRACTS
568 PATENTS PORTFOLIO
50% OF PATENT LICENSED
20 SPIN-OFF COMPANIES

KEY FIGURES
PEDIATRIC ONCOLOGY
2018 DATA

6 NEW R&D AGREEMENTS
15 ONGOING CLINICAL TRIALS
10 NEW RESEARCH PROGRAMS INITIATED

AN **OFFER** SIZED TO YOUR **NEEDS**

- An offer tailored to your company size.
- A guaranteed confidentiality for your data and project.
- Different level of partnership depending on your needs:
  - Consulting and expertise
  - Proof of concept or feasibility
  - R&D collaboration
  - Pre-market validation
  - Joint R&D lab
- An access to high level of national and international experts network.

MORE INFO
techtransfer.institut-curie.org





SIREDO ONCOLOGY CENTER

The SIREDO *(Soin, Innovation, Recherche en oncologie de l'Enfant, aDOlescent et du jeune adulte)* oncology center was created in 2017 with an overall goal of **increasing basic knowledge on pediatric tumors** and **improving the survival of patients** by **fostering bench-to-bedside medicine** for children, adolescents and young adults.

FUNDAMENTAL RESEARCH

Three research groups are focused on childhood cancer research. The main tumors under intense biological scrutiny are **Ewing and other sarcomas, Retinoblastoma**, **Neuroblastoma**, **malignant Rhabdoïd tumors** and **Medulloblastoma**.

Main areas of interest:

- Tumor heterogeneity and cell plasticity
- Immune micro-environment
- Neo-antigens
- Genetics
- Epigenetics
- Multi-Omics approaches

In addition, pediatric oncology research strongly beneficiates from the outstanding medical and scientific environment of Institut Curie.

TRANSLATIONAL RESEARCH

A particular emphasis on biomarkers is at the utmost importance at each step of the management of childhood cancer patients. Many partnerships are in place with efforts towards less invasive techniques and a spatial-temporal follow up of the disease. This is of particular importance for a rational implementation of clinical trials and of biomarker-based protocols.

- Liquid biopsies/non-invasive methods
- Diagnostic, prognostic, and theranostic biomarkers
- Pharmaco-dynamics/pharmaco-genetic markers
- Minimal residual disease
- Clonal evolution of the disease
- Biostatistics and bioinformatics expertise for integration into clinics

A **RESEARCH-CARE CONTINUUM**

MEDICAL ACTIVITY

One of the main aims of the SIREDO center is to provide the best current care for children, adolescents, and young adults with cancer by optimization of the care path in a multidisciplinary and global approach that includes scientific, human, social and ethical dimensions.

MAIN EXPERTISE

- More than 300 new malignant registrations per year
- European center of Reference for Retinoblastoma
- Adolescent and Young adults dedicated Unit.
- INCa CLIP2 pediatric label for early clinical trials
- Leading center in Europe for the number of patients included in ITCC trials
- More than 15 ongoing clinical studies and trials with opportunities of ancillary studies

Molecular pathology board is in place for the SIREDO Center. The identification of new and druggable molecular alterations is critical for adapted patient's management and choice of treatment.



MORE INFO
techtransfer.institut-curie.org

WHY PARTNERING WITH SIREDO ?

→ **Corporate partnership in the field of pediatric precision medicine.**

→ **Access to research tools and tumor models**

- Pre-clinical assessment of potential therapies
- Cell models for pediatric solid tumors
- GEMM mice models for Neuroblastoma and Rhabdoid tumors
- More than 57 established PDX models with many in orthotopic location

→ **Research with the Somatic Genetic Unit** is the national reference center for tumor molecular analyses in a clinical setting, mainly in pediatric oncology.

- Wide technological arsenal
- More than 1250 cases per year
- More than 50 different tumor entities
- Tumor bank with more than 14000 Patients, 15000 tumor samples and 70000 derived products

Janssen Horizon · Bristol-Myers Squibb · MSD AVENIR · Roche · SANOFI · Pfizer

PARTNERING WITH INSTITUT CURIE

Institut Curie conducts projects from basic research to clinical studies in order to:

- Understand mechanisms of pathological development
- Facilitate the transition from basic research to clinical application
- Develop innovative therapeutic and diagnostic techniques in cancer

RESEARCH CENTER

4 domains of excellence:

- Biology, Cancer, Genetics and Epigenetics
- Biology & Chemistry of Radiations, Cell Signaling and Cancer
- Integrative Tumour Biology, Immunology and Environment
- Multiscale Physics-Biology-Chemistry and cancer

TRANSLATIONAL RESEARCH DEPARTMENT

This department provides clinicians and researchers with human and technological resources enabling the development of application-oriented projects.

HOSPITAL GROUP

Three sites in Paris region area welcome patients bearing cancers from the most frequent to the rarest, to offer them state-of-the-art treatments and improve their quality of life.
Institut Curie is an international expert for eye cancers, pediatric tumors, breast cancers and sarcomas.

PLATFORMS

Institut Curie provides a wide range of advanced technological platforms. Their services cover biological complexity from small molecules up to whole organisms and contribute to the progress of basic and translational research projects up to clinical studies.